Publications
- The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis2023 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Multiple Sclerosis and Microbiome2022 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Real-world effectiveness and safety of fingolimod in patients with multiple sclerosis in the Czech Republic: results from core and extension parts of the GOLEMS study up to 48 months2022 | First Faculty of Medicine
- To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection2022 | First Faculty of Medicine
- High-efficacy drugs in early stage of multiple sclerosis2022 | First Faculty of Medicine
- Komentář: Siponimod v léčbě pacientů se sekundárně progresivní roztrou šenou sklerózou (studie EXPAND a její analýzy)2020 | First Faculty of Medicine
- Fingolimod in Real Clinical Practice2017 | First Faculty of Medicine
- Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study2017 | First Faculty of Medicine
- Autoimmune diseases of the central nervous system in cases2017 | First Faculty of Medicine
- Multiple sclerosis2013 | First Faculty of Medicine, Second Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
Loading network view...